 Home > Active Ingredient News > Drugs Articles > Significantly improve multiple health and functional indicators, subcutaneous injection of RNAi therapy announced the latest phase 3 trial results

Significantly improve multiple health and functional indicators, subcutaneous injection of RNAi therapy announced the latest phase 3 trial results

 Last Update: 2021-09-10
 Source: Internet
 Author: User

Tags

specific

graves disease awareness month

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 7, 2021, Alnylam Pharmaceuticals announced the latest results obtained in a phase 3 clinical trial of its RNAi drug vutrisiran in the treatment of patients with transthyretin-mediated (ATTR) amyloidosis

Hereditary transthyretin-mediated (hATTR) amyloidosis is a hereditary and progressive debilitating and fatal disease caused by mutations in the TTR gene

Vutrisiran is a subcutaneously administered RNAi therapeutic drug that is being developed to treat ATTR amyloidosis, including hATTR and wild-type ATTR (wtATTR) amyloidosis

▲Introduction of Onpattro and vutrisiran (picture source: Alnylam official website)

The data obtained this time further supports the primary and secondary endpoint results previously reported in the HELIOS-A trial, which was carried out in 164 patients with hATTR amyloidosis with polyneuropathy

The results of data analysis showed that at the 9th month, the trial reached the primary endpoint and all secondary endpoints

In terms of safety, compared with placebo, vutrisiran showed encouraging safety and tolerability characteristics

Reference materials:

[1] Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting.

[1] Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting.
Retrieved September 7, 2021, from https:// home/20210907005432/en

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Top Product

$49-62/KG FOB

Safe Delivery Freeze Dried Peptides Raw Powder Weight Loss Tirze Peptide Sema 5mg 10mg

CAS No.: 2023788-19-2

Pharmacy Grade

$120.00/UNIT FOB

Hot Sale 1-Adamantanamine Hydrochloride /1-Adamantanamine HCl CAS 665-66-7

CAS No.: 665-66-7

Pharmacy Grade

$20-25/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.